NC-PHARM - мы работаем для профессионалов в сфере фармации
www.ncpharm.ru / Пресс-центр / Международные новости

ПРЕСС-ЦЕНТР

ПОЛЕЗНАЯ ИНФОРМАЦИЯ

НОВОСТИ КОМПАНИИ

Новости компании
06.12.2011
Субстанция прибыли

"В газете Коммерсант Здравоохранение опубликован обзор современного рынка фармацевтических субстанций. В качестве основного эксперта по теме высказал свое мнение Петр Белый, председатель Совета Директоров компании Эн Си Фарм."
08.11.2011
Пора по БАДам

Опубликовано новое интервью председателя Совета Директоров фармацевтической компании Эн Си Фарм Петра Белого на тему привлекательности сегмента ОТС и БАДов.
01.08.2011
Коммерсант Деньги: «Тяжелый фармацевтический случай»

Аптечный кризис – острая тема последних месяцев. Аналитический материал на эту тему опубликовали в издании «Коммерсант Деньги».

РОСЗДРАВНАДЗОР

Росздравнадзор

Международные новости

20.02.2010
CORRECTED - FDA grants priority review to Novartis drug Tasigna in myeloid leukemia

In our story from Friday headlined "FDA grants priority review to Novartis drug Tasigna in myeloid leukemia", please read in the dateline "19 February 2010"aÃ?' instead of "19 December 2010".

20.02.2010
Physio-Control, after three years of scrutiny, gets FDA OK for full sales [Seattle Times]

Feb. 20--Redmond-based Physio-Control said Friday it received Food and Drug Administration approval to resume unrestricted worldwide shipments of its external defibrillators, ending a three-year effort to convince regulators its quality-control systems are up to par. The company, a unit of Medtronic.

19.02.2010
FDA approves Rituxan for treatment of chronic lymphocytic leukemia

19 February 2010 - The US Food and Drug Administration announced yesterday that it has approved Rituxan to treat certain patients with chronic lymphocytic leukemia, a slowly progressing blood and bone marrow cancer. Rituxan, an anti-cancer drug, is intended for patients with CLL who are beginning chemotherapy for the first time and for those who ...

19.02.2010
Neurosurgeons hope compound extends lives: Early-stage trials under way at Allegheny General approved by FDA [Pittsburgh Post-Gazette]

Feb. 19--John Rotella of Bridgeville began «losing names and what was going on.» Donald Marsh of Indiana, Pa. began having «dizzy spells and light-headedness.» Different symptoms but the same diagnosis: They each had a glioma, the most common form of a brain tumor. The two also ended up having the same treatment at Allegheny General Hospital.

19.02.2010
Novartis announces receipt of FDA priority review for Tasigna

Novartis Pharmaceuticals Corporation today said that its Tasigna 200 mg capsules has been granted priority review by the US Food and Drug Administration for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase.

17.02.2010
Abbott offers to buy 20% of Solvay Pharma India

US drug maker Abbott Laboratories and its unit Abbott Capital India have offered to buy up to one million shares or 20% of Solvay Pharma India, a subsidiary of Belgian chemicals and pharmaceuticals group Solvay.

17.02.2010
Alkermes reports positive results from Phase I constipation study Alkermes, a biotechnology company, has reported positive topline data from a Phase I clinical study of ALKS 37, an orally active, peripherally-restricted opioid antagonist with potential to block the effects of opioid agonists on gastrointestinal motility, commonly referred to as opioid-induced constipation, or OIC.

17.02.2010
Angiotech Pharmaceuticals and partner Athersys announces completion of patient enrollment in phase I study of Multistem(R) in acute myocardial infarction VANCOUVER, Feb. 17Athersys, Inc. and Angiotech Pharmaceuticals, Inc. announced that Athersys has completed patient enrollment for its phase I clinical trial of MultiStem, its allogeneic stem cell therapy product, administered to individuals following acute myocardial infarction, more commonly referred to as a heart attack.
© 2010 – 2014 NC Pharm  поставщик фармацевтических субстанций.
Все права на логотипы и товарные знаки принадлежат их владельцам.
Тел./Факс: +7 (495) 984 7579
E-mail: info@ncpharm.ru